Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SORD | Q00796 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21047630 | 0.91 | BCHE (0.66) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL21047636 | 0.91 | BCHE (0.69) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL23771247 | 0.82 | HDAC11 (0.63) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL4941906 | 0.78 | BCHE (0.56) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL4941909 | 0.78 | BCHE (0.56) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL2674037 | 0.77 | BCHE (0.90) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL2676103 | 0.77 | BCHE (0.96) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL717865 | 0.76 | BCHE (1.00) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL2241920 | 0.76 | BCHE (1.00) | BCHEACHEHTR3ATP53TRPC3 | |
| SCHEMBL4674485 | 0.74 | BCHE (0.73) | BCHEACHEHTR3ATP53TRPC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | BCHE 2232/4885ACHE 4022/4885HTR3A 3522/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | BCHE 2232/4885ACHE 4022/4885HTR3A 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.